Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Vaidya P, Bera K, Gupta A, Wang X, Corredor G, Fu P, et al. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction. Lancet Digit Health. 2020;2(3):e116-e128.

Zhou L, Yu W, Jayabalan DS, Niesvizky R, Jaffrey SR, Huang X, et al. Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. Front Cell Dev Biol. 2020;8:605989.

Saqi A, Mukhopadhyay S, Butt Y, Doxtader E, Heymann JJ, Larsen BT, et al. E-cigarette or vaping product use-associated lung injury: What is the role of cytologic assessment? Cancer Cytopathol. 2020;128(6):371-380.

Marzio A, Pagano M. Loss of the deubiquitinase OTULIN promotes hepatocellular carcinoma (HCC) in an mTOR-dependent manner. Cell Death Differ. 2020;27(5):1455-1456.

Patel SS, Lipschitz M, Pinkus GS, Weirather JL, Pozdnyakova O, Mason EF, et al. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Mod Pathol. 2020;33(7):1380-1388.

Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.

Bagheri S, Pantrangi M, Sodhi SK, Bagheri S, Oellers P, Scholl HP. A NOVEL LARGE HOMOZYGOUS DELETION IN THE CELLULAR RETINALDEHYDE-BINDING PROTEIN GENE (RLBP1) IN A PATIENT WITH RETINITIS PUNCTATA ALBESCENS. Retin Cases Brief Rep. 2020;14(1):85-89.

Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, et al. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020;146(10):2694-2702.

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020;95(12):1553-1561.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, et al. Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Mod Pathol. 2020;33(2):319.